ТРОМБОЦИТОПЕНИЯ У БОЛЬНЫХ МНОГОПРОФИЛЬНОГО СТАЦИОНАРА И ВОЗМОЖНЫЕ ПУТИ ОПТИМИЗАЦИИ ЕЕ ОЦЕНКИ
https://doi.org/10.21518/2079-701X-2017-20-14-19
Аннотация
Об авторах
Н. Ю. СемиголовскийРоссия
доктор медицинских наук, профессор.
Санкт-Петербург.
Т. В. Вавилова
Россия
доктор медицинских наук, профессор.
Санкт-Петербург.
В. А. Кащенко
Россия
доктор медицинских наук.
Санкт-Петербург.
С. Н. Семиголовский
Россия
Санкт-Петербург.
А. А. Сапегин
Россия
кандидат медицинских наук.
Санкт-Петербург.
Список литературы
1. Вагнер Д.О., Вербицкий В.Г., Шлык И.В., Курыгин Ал.А. Негативные последствия антисекреторной терапии и способы их предупреждения у пострадавших с обширными ожогами. Вестник хирургии им. И.И. Грекова, 2015, 174(3): 108-112.
2. Дуткевич И.Г., Сухомлина Е.Н., Селиванов Е.А. (2010). Основы клинической гемостазиологии. СПб.: ООО ИПК Коста, 2010. 144 с.
3. Енисеева Е.С., Власюк Т.П. Острый стенттромбоз у больного с гепарин-индуцированной тромбоцитопенией. Сибирский мед. журнал, 2013, 5: 130-131.
4. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N. Engl. J. Med., 2006, 355(8): 809-817.
5. Arnold DM, Nazi I, Warkentin TE, Smith JW, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus. Med. Rev., 2013, 27(3): 137-145.
6. Aster RH. Drug-induced immune cytopenias. Toxicology, 2005, 209: 149-153.
7. Bangia AN, Kamath N, Mohan V. Ranitidineinduced thrombocytopeniа: a rare drug reaction. Indian J. Pharmacol., 2011, 43: 76-77.
8. Barilla D, Martinelli GL, Cotroneo A, Romano A, Iacopino P. Thrombosis due to Heparin-induced Thrombocytopenia in Cardiac Surgery: is Fondaparinux an Effective Treatment? J Cardiovasc Dis Diagn, 2016, 4(3): 240-245.
9. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol, 1993, 84(2): 322-328.
10. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2012, 120(20): 4160-4167.
11. Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology, 2014, 30(2): 55-65.
12. Datta I, Ball CG, Rudmik L, et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes, 2010, 4: 1-21.
13. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparininduced thrombocytopenia. Clinical and diagnostic implications – a review. Arch Pathol Lab Med, 2000, 124(11): 1657-1666.
14. Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood, 1998, 92(7): 2359-2365.
15. Greinacher A, Selleng K. Thrombocytopenia in the Intensive Care Unit Patient. ASH Education Book, 2010, 2010(1): 135-143.
16. Greinacher A, Warkentin ThE. Heparin-induced thrombocytopenia. New York, N.Y: Marcel Dekker. 2004: 106-107.
17. Jang I-K, Hursting MJ. Thrombocytopenia when heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation, 2005, 111: 2671-2683.
18. Kang M, Alahmadi M, Sawh S, Kovacs MJ, LazoLangner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood, 2015, 125(6): 924-929.
19. Levi M. Platelets in sepsis. Hematology, 2005, 10(Supplement 1): 129-131.
20. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST Journal, 2012, 141: e495S-e530S.
21. Motokawa S, Torigoshi T, Maeda Y, et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord, 2011, 12: 22-34.
22. Pearson M, Nadeau Ch, Blais N. Correlation of ELISA Optical Density With Clinical Diagnosis of Heparin-Induced Thrombocytopenia. A Retrospective Study of 104 Patients With Positive Anti-PF4/Heparin ELISA. Clin Appl Thromb Hemost, 2014, 20(4): 349-354.
23. Pouplard C, May M-A, Iochmann S, et al. Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin: Clinical Implications for Heparin-Induced Thrombocytopenia. Circulation, 1999, 99: 2530-2536.
24. Salter BS, Weiner MW, Trinh MA, et al. HeparinInduced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol, 2016, 67: 2519-2532.
25. Selleng K, Warkentin TE, Greinacher A. Heparininduced thrombocytopenia in intensive care patients. Crit Care Med, 2007, 35: 1165-1176.
26. Wilke T, Tesch S, Scholz A, et al. The costs of heparin-induced thrombocytopenia: a patientbased cost of illness analysis. J Thromb Haemost, 2009, 7: 766-773.
27. Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Frequent of-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)-findings from the GerHIT multi-centre registry study. Thrombosis research, 2014, 134: 29-35.
28. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest, 2005, 127: 35-45.
29. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost, 2015, 41(1): 49-60.
30. Warkentin TE. Clinical picture of heparininduced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost, 2016, 116(5): 813-822.
31. Warkentin TE, Aird WC, Rand JH. Plateletendothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc of Hematol Educ Program), 2003: 497-419.
32. Warkentin TE, Greinacher A. Management of heparin-induced thrombocytopenia. Curr Opin Hematol, 2016, 5: 462-470.
33. Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest, 2007, 132(4): 1108–1110.
34. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep., 2003, 2(2): 148-157.
35. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med, 2001, 344: 1286-1292.
36. Warkentin TE, Sheppard JA, Heels-Ansdell D et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest, 2013, 144(3): 848-858.
Рецензия
Для цитирования:
Семиголовский НЮ, Вавилова ТВ, Кащенко ВА, Семиголовский СН, Сапегин АА. ТРОМБОЦИТОПЕНИЯ У БОЛЬНЫХ МНОГОПРОФИЛЬНОГО СТАЦИОНАРА И ВОЗМОЖНЫЕ ПУТИ ОПТИМИЗАЦИИ ЕЕ ОЦЕНКИ. Медицинский Совет. 2017;(20):14-19. https://doi.org/10.21518/2079-701X-2017-20-14-19
For citation:
Semigolovskii SY, Vavilova TV, Kashchenko VA, Semigolovskii SN, Sapegin AA. THROMBOCYTOPENIA IN THE STRUCTURE OF HEMATOLOGICAL DISORDERS IN PATIENTS OF A MULTIPROFILE HOSPITAL AND POSSIBLE WAYS TO OPTIMIZE ITS EVALUATION. Meditsinskiy sovet = Medical Council. 2017;(20):14-19. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-14-19